Floatz logo

Apl-4098

Acute Myeloid Leukemia (AML)

Apollo Therapeutics LtdPhase 1Active
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

35 Active assets in the Acute Myeloid Leukemia (AML) cohort.

Asset / SponsorPhaseRating
Dcp-001
Mendus
Phase 2B
CHLORAMBUCIL
Clavis Pharma
Phase 3B
HUMAN HEMATOPOIETIC PROGENITOR CELL, MARROW DERIVED
Hannover Medical School
Phase 3B
Blinatumomab
Ascentage Pharma Group Inc.
Phase 2B
Axitinib
Pfizer
Phase 2B

View all 50 →

Same molecule, other indications

Apl-4098 is also rated in:

acute myeloid leukemiaDormant
CC
Indicative ·
43 / 100
View asset →
therapy related acute myeloid leukemia and myelodysplastic syndromeDormant
CC
Indicative ·
43 / 100
View asset →
myelodysplastic syndrome with excess blastsDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →